B
179.35
-0.92 (-0.51%)
| Previous Close | 180.27 |
| Open | 177.15 |
| Volume | 276,034 |
| Avg. Volume (3M) | 370,548 |
| Market Cap | 20,238,571,520 |
| Price / Earnings (Forward) | 384.62 |
| Price / Sales | 6.06 |
| Price / Book | 5.96 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2025 - 28 Feb 2025 |
| Profit Margin | -25.50% |
| Operating Margin (TTM) | -13.90% |
| Diluted EPS (TTM) | -8.18 |
| Quarterly Revenue Growth (YOY) | 39.50% |
| Total Debt/Equity (MRQ) | 30.54% |
| Current Ratio (MRQ) | 1.94 |
| Operating Cash Flow (TTM) | -4.56 B |
| Levered Free Cash Flow (TTM) | -5.26 B |
| Return on Assets (TTM) | -9.58% |
| Return on Equity (TTM) | -23.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BeiGene, Ltd. | Bullish | Bearish |
AIStockmoo Score
-0.2
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Insiders | 17.79% |
| % Held by Institutions | 44.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 300.00 (Morgan Stanley, 67.27%) | Buy |
| Median | 260.00 (44.97%) | |
| Low | 235.00 (JP Morgan, 31.03%) | Buy |
| Average | 265.00 (47.76%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 207.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 03 Dec 2024 | 300.00 (67.27%) | Buy | 206.01 |
| TD Cowen | 13 Nov 2024 | 260.00 (44.97%) | Buy | 195.45 |
| JP Morgan | 22 Oct 2024 | 235.00 (31.03%) | Buy | 220.63 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | - | 207.62 | -1,037,017 | -215,305,470 |
| OYLER JOHN | - | - | 0 | 0 |
| WANG XIAODONG | - | 187.50 | -41,760 | -7,830,000 |
| Aggregate Net Quantity | -1,078,777 | |||
| Aggregate Net Value ($) | -223,135,470 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 197.56 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OYLER JOHN | Officer | 14 Dec 2024 | Option execute | 1,300,000 | - | - |
| WANG XIAODONG | Director | 10 Dec 2024 | Automatic sell (-) | 41,760 | 187.50 | 7,830,000 |
| WANG XIAODONG | Director | 10 Dec 2024 | Option execute | 41,760 | - | - |
| BAKER BROS. ADVISORS LP | Director | 09 Dec 2024 | Sell (-) | 1,037,017 | 207.62 | 215,305,470 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |